Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 349

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trial

Svensson, Björn, Boonen, Annelies, Albertsson, Kristina, van der Heijde, Désirée, Keller, Catharina, Hafström, Ingiäld, for the BARFOT Study Group·2005·Arthritis & Rheumatism

Abstract

Objective: To assess the efficacy of low‐dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA). Methods: At the start of their initial treatment with a disease‐modifying antirheumatic drug (DMARD), patients with early (duration ≤1 year) active RA were randomly assigned to receive either 7.5 mg/day prednisolone or no prednisolone for 2 years. Radiographs of the hands and feet were obtained at baseline and after 1 and 2 years and scored according to the Sharp score as modified by van der Heijde. Remission was defined as a Disease Activity Score in 28 joints of <2.6. Bone mineral density was measured by dual x‐ray absorptiometry at baseline and after 2 years. Results: Of the 250 patients included, 242 completed the study and 225 had radiographs available both at baseline and at 2 years. At 2 years, the median and interquartile range (IQR) change in total Sharp score was lower in the prednisolone group than in the no‐prednisolone group (1.8 [IQR 0.5–6.0] versus 3.5 [IQR 0.5–10];P= 0.019). In the prednisolone group, there were fewer newly eroded joints per patient after 2 years (median 0.5 [IQR 0–2] versus 1.25 [IQR 0–3.25];P= 0.007). In the prednisolone group, 25.9% of patients had radiographic progression beyond the smallest detectable difference compared with 39.3% of patients in the no‐prednisolone group (P= 0.033). At 2 years, 55.5% of patients in the prednisolone group had achieved disease remission, compared with 32.8% of patients in the no‐prednisolone group (P= 0.0005). There were few adverse events that led to withdrawal. Bone loss during the 2‐year study was similar in the 2 treatment groups. Conclusion: Prednisolone at 7.5 mg/day added to the initial DMARD retarded the progression of radiographic damage after 2 years in patients with early RA, provided a high remission rate, and was well tolerated. Therefore, the data support the use of low‐dose prednisolone as an adjunct to DMARDs in early active RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.21298

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 349

Metadata

Authors
Svensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafström, I., & for the BARFOT Study Group
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2005-10-27
Volume
52
Issue
11
Pages
3360-3370
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2084911737
Cited by
349
References
36
FWCI
11.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trial. https://app.cochat.ai/papers/10.1002/art.21298
The paper
Svensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafström, I., & for the BARFOT Study Group. (2005). Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.21298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.